RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK–positive lung cancer
نویسندگان
چکیده
منابع مشابه
Rational Polytherapy with Antiepileptic Drugs
Approximately 30-40% of patients do not achieve seizure control with a single antiepileptic drug (AED). With the advent of multiple AEDs in the past 15 years, rational polytherapy, the goal of finding combinations of AEDs that have favorable characteristics, has become of greater importance. We review the theoretical considerations based on AED mechanism of action, animal models, human studies ...
متن کاملCombining antiepileptic drugs—Rational polytherapy?
The global introduction of 14 new antiepileptic drugs (AEDs) over the past 20 years as adjunctive treatment in refractory epilepsy has triggered an increased interest in optimising combination therapy. With a widening range of available mechanisms of AED action, much activity has been focused on the defining and refining "rational polytherapy" with AEDs that have differing pharmacological prope...
متن کاملA mouse model for EML4-ALK-positive lung cancer.
EML4-ALK is a fusion-type protein tyrosine kinase that is generated in human non-small-cell lung cancer (NSCLC) as a result of a recurrent chromosome inversion, inv (2)(p21p23). Although mouse 3T3 fibroblasts expressing human EML4-ALK form transformed foci in culture and s.c. tumors in nude mice, it has remained unclear whether this fusion protein plays an essential role in the carcinogenesis o...
متن کاملRational conversion from antiepileptic polytherapy to monotherapy.
For patients with epilepsy, the goal of treatment is to achieve seizure freedom with minimal or no adverse events. Around 60%-70% of newly diagnosed patients will achieve this goal with single antiepileptic drug (AED) therapy, and there is universal agreement that prescription of a single agent constitutes best practice for such patients. For the 30%-40% of patients with poorly controlled epile...
متن کاملTargeting stemness is an effective strategy to control EML4-ALK+ non-small cell lung cancer cells
The fusion between anaplastic lymphoma kinase (ALK) and echinoderm microtubule-associated protein-like 4 (EML4) is a causative factor in a unique subset of patients with non-small cell lung carcinoma (NSCLC). Although the inhibitor crizotinib, as it blocks the kinase activity of the resulting EML4-ALK fusion protein, displays remarkable initial responses, a fraction of NSCLC cases eventually be...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Nature Medicine
سال: 2015
ISSN: 1078-8956,1546-170X
DOI: 10.1038/nm.3930